AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

1. (Previously Presented) A tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

n represents an integer of 0 to 6;

R_1 represents hydrogen or C_{1-6} alkyl;

R_2 and R_3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen,

wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C_{1-6}

alkoxycarbonyl, and C_{1-6} alkyl optionally substituted by hydroxy, carboxy, C_{1-6} alkoxy, or C_{1-6} alkoxycarbonyl,

or

R_2 represents C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{1-6} alkyl substituted by amino, hydroxy, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino;

R_3 represents hydrogen, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{1-6} alkyl optionally substituted by amino, hydroxy, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino; and

R_4 represents hydrogen, halogen, C_{1-6} alkylthio, C_{1-6} alkyl optionally substituted by mono-, di-, or tri-halogen, or C_{1-6} alkoxy optionally substituted by mono-, di-, or tri-halogen.

2. (Previously Presented) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

n represents an integer of 0 or 1;

R_1 represents hydrogen;

R_2 and R_3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen,

wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of benzyl, hydroxy, carboxy, oxo, aminocarbonyl, C_{1-6} alkoxycarbonyl, and C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, or C_{1-6} alkoxycarbonyl,

or

R_2 represents C_{1-6} alkyl substituted by hydroxy, amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino;

R_3 represents hydrogen, C_{1-6} alkyl optionally substituted by hydroxy, amino, C_{1-6} alkylamino, or di(C_{1-6} alkyl)amino; and

R_4 represents hydrogen, halogen, C_{1-6} alkyl optionally substituted by mono-, di-, or tri-halogen, or C_{1-6} alkoxy optionally substituted by mono-, di-, or tri-halogen.

3. (Previously Presented) The tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein

n represents an integer of 0 or 1;

R_1 represents hydrogen;

R_2 and R_3 together with the nitrogen atom to which they are attached, form a pyrrolidinyl optionally substituted by oxo, piperidinyl optionally substituted by hydroxy, carboxy, aminocarbonyl, C_{1-6} alkoxycarbonyl, or C_{1-6} alkyl optionally substituted by hydroxy, piperazinyl optionally substituted by benzyl, homopiperidinyl, or morpholinyl,

or

R_2 represents C_{1-6} alkyl substituted by hydroxy, or di(C_{1-6} alkyl)amino; R_3 represents hydrogen, or C_{1-6} alkyl; and R_4 represents hydrogen, fluoro, chloro, bromo, C_{1-6} alkyl optionally substituted by mono-, di-, or tri-halogen, or C_{1-6} alkoxy.

4. (Previously Presented) A tetrahydro-naphthalene derivative, its tautomeric or stereoisomeric form, or a salt thereof selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-pyrrolidin-1-yl-4-(-trifluoromethyl)benzyl]urea;

N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(3-bromo-4-piperidin-1-ylbenzyl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;

N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1- yl-4-(trifluoromethyl)benzyl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;

ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate; and

N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea.

5. (Previously Presented) A pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient, and a pharmaceutically acceptable excipient.

Claims 6 - 26. (canceled)

27. (Previously Presented) The tetrahydro-napthalene derivative of claim 4, its tautomeric or stereoisomeric form, or a salt thereof wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea.

28. (Previously Presented) The tetrahydro-napthalene derivative of claim 4, its tautomeric or stereoisomeric form, or a salt thereof wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N'-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea.